{"name":"Alexion (AstraZeneca Rare Disease)","slug":"alexion","ticker":"AZN","exchange":"NASDAQ","domain":"alexion.com","description":"Alexion was an ancient physician. His name and profession are known from a lamentation on his sudden death, authored by his close friend Cicero. His name suggests that he was Greek.","hq":"Boston, MA","founded":0,"employees":"96100","ceo":"Marc Dunoyer (Head of Alexion)","sector":"Rare Disease","stockPrice":185.61,"stockChange":-2.11,"stockChangePercent":-1.12,"marketCap":"$287.9B","metrics":{"revenue":60438999040,"revenueGrowth":12.5,"grossMargin":81.5,"rdSpend":886000000,"netIncome":603400000,"cash":7674999808,"dividendYield":1.68,"peRatio":27.9,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Ultomiris patent cliff ($1.5B at risk)","drug":"Ultomiris","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-01","label":"Strensiq patent cliff ($500M at risk)","drug":"Strensiq","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-02","type":"regulatory","headline":"AstraZeneca Rare Disease receives FDA approval for Ultomiris for the treatment of generalized myasthenia gravis","summary":"The FDA has approved Ultomiris for the treatment of generalized myasthenia gravis, expanding its indication to include this rare autoimmune disorder.","drugName":"Ultomiris","sentiment":"positive"},{"date":"2022-10-25","type":"earnings","headline":"AstraZeneca Rare Disease reports Q3 2022 earnings","summary":"AstraZeneca Rare Disease reported its Q3 2022 earnings, with revenue growth driven by strong sales of its rare disease therapies.","drugName":"","sentiment":"neutral"},{"date":"2022-06-01","type":"deal","headline":"AstraZeneca Rare Disease partners with a leading research institution to develop new treatments for rare diseases","summary":"AstraZeneca Rare Disease has partnered with a leading research institution to develop new treatments for rare diseases, further expanding its pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNcV9kSS0wellCclpjNVNGbmNLVU9xUS1LblJjNnNwM1Vld1drbXFyNDVRQ3ZGYnlVVlRhV1lycEJlaEJfb05PYkNhbGdFUVdnaXVvRXQ0SXo2dWRsY0Z0aGRFeF9haGZNU2lHMXZqNEhmZG9qVk02N3VTZGRCUGFEd3ZKdWVGRFJhemhwNWFSZ3V1ZTZzd243RzVrMDlmQV9RZ3d5NnIxSHRrdEpwUjlxN2FVYUVHSFYtQ3lMMTg4VHFKNTljbHlBbVZtYnNqTnBhMS1JY2w5S2trYlJ0ZFJsN2E3bTBqNmxnTDlOXw?oc=5","date":"2026-02-06","type":"pipeline","source":"The Chronicle-Journal","summary":"The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance - The Chronicle-Journal","headline":"The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNTllOcGtwUGc1TXEwdFBHXy1wV1VPcWQ3eEZaWkpaX1FxV1hLSEZDYWprdHM3ZU52bEVYbFJoa0hfUGtCOHlIN0o5UEZjTzNhMTEwWjg4cV9CUl9mTE1ORXVZLWhZb3I3YTgxZEROeFNpV01JNUxBczRJRTlEbVNabXd4M1k5UWhSNzNmQWk5VmwxRTFidWd3YTVB?oc=5","date":"2025-12-05","type":"deal","source":"The Pharma Letter","summary":"Neurimmune expands collaboration with AstraZeneca - The Pharma Letter","headline":"Neurimmune expands collaboration with AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPM0dHZndOZTBhamJzTC1NTFF4ZEc3UlptTWV6dWQ1czF5T2d6Y2xXNTgtLWFzcjdSUGVPTHJoaTNVLUpTbWN1U0VJMnF0MW9JNlhHWVd6a3NJbXpXTE4yY0lPcG13YXhiRUxzamhHNWVKcU9WU0RuR25QcEdPTzhRVXB1YkU1dUVwdFNEcGhtM2lfaVJBd3FGNGRoTy1kR0t5NTNSWnd0Nkg0Qkk?oc=5","date":"2025-07-16","type":"trial","source":"Fierce Biotech","summary":"AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test - Fierce Biotech","headline":"AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOM2dQbmtUN2FJNGI1NWVHYmFLNzJMeEc5VUtlcjZ0b1o1eTJ6YUNyX1FqVlM3NHVfZzdIWXlLU1lqWUVKU0NEYUlLODY0SFVmbTJxZTJ4YlNXd1RIc0l1M0JYQWtXbVhYMDlpZnJQaFE4aHlUaWpFeXNNdEoyVE5HalZIbTlkcDBYY1doQkN0emhnNjFKSXA4bUx2RHRhRzVmVmZhWEp1aWhXT0Vfb0Y2dGc2SQ?oc=5","date":"2025-07-16","type":"pipeline","source":"MedCity News","summary":"AstraZeneca Blockbuster Prospect Is a Bust in Pivotal Test in Light Chain Amyloidosis - MedCity News","headline":"AstraZeneca Blockbuster Prospect Is a Bust in Pivotal Test in Light Chain Amyloidosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPSVE5RV9uRXMtZnFaS2h3R2dvblQ0M3IyS0JSakVsZmtfNFBpME5oenU3QktIdlA3d2U2cjNuY2pJektQVXo5UzlMU3MyQlV5V1BMdk1ZTFZKaDlQSDEtaTNfRGU1Sllfc3dWR0p5d3VzWFdyZ3YyNWlyTWJ6dWFtQUhJYVRzU1JuX1g0Y2U0MzV2RTIwenczTHBLdTBqNlNCR2NrTWZjOA?oc=5","date":"2025-02-06","type":"earnings","source":"BioSpace","summary":"AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations - BioSpace","headline":"AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOS2pmbGVaUmVBbGR5TjdlRG9zVTdyaG14YlJUTm5oMmJXYU1wWnlOVHpIbEpjSmd3OVNkN0VTR182QW51Vjl0ZGNRN3E0M1ZmVlU2TEdCYXotRmpHREJIQVBUSmlQZHQtN1p3NVp6emNzemdtY3k0QWhMQVlzeUJDbngzTGFWdm5IZVdhajY1cUdKVGM2Y0RuV01Gdy1Vc2oz?oc=5","date":"2024-12-03","type":"pipeline","source":"Pharma Voice","summary":"How Alexion markets a rare disease drug by ‘starting with the end in mind’ - Pharma Voice","headline":"How Alexion markets a rare disease drug by ‘starting with the end in mind’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOWklPWXVFM29tZlk3VVJqb3FlYUhfbmFvUFFDSTJ6aWVGNndmcm1Uam14dzhZdTFqejM1R3JkZ2FQY1I4VmZoc0N1MHVHejFiODZscG5YNkNGcFBUZmNPT3czYnRsRGdSejZ0XzhONklIYm5zdjFLUm1TY3lSR2psckowQW1MczlfLS0tcmoxU0xlaFZ2MVhoOVMwdw?oc=5","date":"2024-03-14","type":"deal","source":"AstraZeneca","summary":"AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline - AstraZeneca","headline":"AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQRnZwc1I0cTNoRWdPWUFiOERHa01pN0laekt2MnNDT21WWTFWTmtYelJtZFpONWdUYWkzWEZFVm4weV9aREY4T216TDhaZlBJY1lUbFBSTi1GWEh3eFQ4Z1dsektNd1A0SDJaLWpmSXBlQTI5eVZiaTRGTk5hcXFmMjdrcDJlc3FnQ09xNFk4TDB2eGt1NkZCSUt5NE00aFNwUDVRd2FKUDI0OXFVUlF5VkZ5Q1M?oc=5","date":"2024-03-14","type":"deal","source":"Investopedia","summary":"AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline - Investopedia","headline":"AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQaUtROHZjaTdpbzBrVm5hVFMydFZYanpFa0dYRmlsMDN5REx1QkQ0M1plSGc4UERnNDFlMWxfWVpDMEMyRVVrWjd1QzBjaVFrOG1OaVpKc2R4ZEdDbEdzU3c5RFY1ekZwUGpaMS0yS0NVMlNLSmV2N3FxZW9rYjNsbWs1azVRZU1HRUp0amFlNC10QWlhTWlic2tlcG5EODNqVEg0T0h4UnVBdjc5dnhBM2FlYTZBQQ?oc=5","date":"2023-07-28","type":"deal","source":"AstraZeneca","summary":"Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies - AstraZeneca","headline":"Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxON0dVTlpsWHdpQlJzcTVWQ0Q2ZWYtaktWLUQxaVlDaDNrU2w5ZVZxNTlJSS1BdS1BVW11Z3ZKalQ3dkhrN0xhenVaUl9tSHVWcmp3ZF9QYWlHbHVWd1l2M1F3WFQ3eDUyclNZTzdkQmdyR0k5NDI4NzZqbnRWYXhoMTBVcjJzanozSVFzamwwQlEwaWFhMVF1LW8tQ3QxaUF3SlBwTkpCckNfRjU4bExtX2VFWQ?oc=5","date":"2023-07-28","type":"deal","source":"reuters.com","summary":"AstraZeneca's rare disease arm in $1 billion deal for Pfizer gene therapies - reuters.com","headline":"AstraZeneca's rare disease arm in $1 billion deal for Pfizer gene therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxONW9oQTh1OGFqX1VSYjRwUi1tSzV5Nm9QZWhMYlQwRk5MR3ZwRjJadk94YUVVeG50aWl5eTZlZDd2T2tXRnhrMXVZNnowblZWbVF0d29vYmNPRE9VSTBlbTRJYXl2NkYyZkFRamZlX3FSdlJ5aVJKZkM5d2wxQXQ2MjlBSFQzaldIQ1ZFRlk5Y0lKMUVSeGRLQVVfOHdDenc0enRrTW5hQlYyOUVCWUx3TjZ0R3cyNFpqTkJvZzZhLTNRc2xXd2dUWGxvZUxERHBYRXc?oc=5","date":"2022-11-16","type":"pipeline","source":"Business Wire","summary":"Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics - Business Wire","headline":"Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOUzRBZlNJaDJZMDdpQkhWbGNtcEhQa1dTMWtMeFM3UUp4MGt2M2ZZcVg1dkdTWHJsZUd6YTZFWFJ0S3RoNkFaeGMxVmt4SFdyTnQ2QkY0VzJrSWhRWTZ5Y3dKbnRiVlBWcVVCSXI0NlRsbS1tR1dHdU9JRUdSN2l2N2dYUjNlUQ?oc=5","date":"2021-07-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"AstraZeneca concludes Alexion acquisition for $39bn - Pharmaceutical Technology","headline":"AstraZeneca concludes Alexion acquisition for $39bn","sentiment":"neutral"}],"patents":[{"drugName":"Strensiq","drugSlug":"asfotase-alfa","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":500000000},{"drugName":"Ultomiris","drugSlug":"ravulizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Biogen","Sanofi Genzyme","Shire (Takeda)"],"therapeuticFocus":["Hemophilia","Rare Immunology","Metabolic Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":3082000000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":3082000000,"period":"2016-12-31"},{"value":2602532000,"period":"2015-12-31"},{"value":2603000000,"period":"2015-12-31"},{"value":2233733000,"period":"2014-12-31"},{"value":2233733000,"period":"2014-12-31"}],"grossProfit":48106000000,"grossProfitHistory":[{"period":"2025-12-31","value":48106000000},{"period":"2024-12-31","value":43866000000},{"period":"2023-12-31","value":37543000000},{"period":"2022-12-31","value":31960000000}],"rdSpend":886000000,"rdSpendHistory":[{"period":"2025-12-31","value":14232000000},{"period":"2024-12-31","value":13583000000},{"period":"2023-12-31","value":10935000000},{"period":"2022-12-31","value":9762000000}],"sgaSpend":20774000000,"operatingIncome":13327000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":13327000000},{"period":"2024-12-31","value":10251000000},{"period":"2023-12-31","value":8722000000},{"period":"2022-12-31","value":4512000000}],"netIncome":603400000,"netIncomeHistory":[{"period":"2025-12-31","value":10225000000},{"period":"2024-12-31","value":7035000000},{"period":"2023-12-31","value":5955000000},{"period":"2022-12-31","value":3288000000}],"eps":6.54,"epsHistory":[{"period":"2025-12-31","value":6.54},{"period":"2024-12-31","value":4.5},{"period":"2023-12-31","value":3.81},{"period":"2022-12-31","value":2.11}],"cash":5711000000,"cashHistory":[{"period":"2025-12-31","value":5711000000},{"period":"2024-12-31","value":5488000000},{"period":"2023-12-31","value":5840000000},{"period":"2022-12-31","value":6166000000}],"totalAssets":18103000000,"totalLiabilities":65355000000,"totalDebt":29149000000,"equity":48667000000,"operatingCashflow":14575000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":14575000000},{"period":"2024-12-31","value":11861000000},{"period":"2023-12-31","value":10345000000},{"period":"2022-12-31","value":9808000000}],"capex":-5905000000,"capexHistory":[{"period":"2025-12-31","value":-5905000000},{"period":"2024-12-31","value":-4586000000},{"period":"2023-12-31","value":-3778000000},{"period":"2022-12-31","value":-2571000000}],"freeCashflow":8670000000,"dividendsPaid":-4971000000,"buybacks":null,"employees":96100,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5061000000,"ebit":4307000000,"ebitda":5673000000,"period":"2026-03-31","revenue":15288000000,"epsBasic":1.99,"netIncome":3080000000,"rdExpense":3492000000,"epsDiluted":1.97,"grossProfit":12610000000,"operatingIncome":4246000000},{"sga":5645000000,"ebit":3113000000,"ebitda":4381000000,"period":"2025-12-31","revenue":15503000000,"epsBasic":1.5,"netIncome":2326000000,"rdExpense":3862000000,"epsDiluted":1.49,"grossProfit":12385000000,"operatingIncome":2978000000},{"sga":5233000000,"ebit":3678000000,"ebitda":5227000000,"period":"2025-09-30","revenue":15191000000,"epsBasic":null,"netIncome":2533000000,"rdExpense":3663000000,"epsDiluted":null,"grossProfit":12390000000,"operatingIncome":3583000000},{"sga":5007000000,"ebit":3566000000,"ebitda":4955000000,"period":"2025-06-30","revenue":14457000000,"epsBasic":1.58,"netIncome":2450000000,"rdExpense":3548000000,"epsDiluted":1.57,"grossProfit":11984000000,"operatingIncome":3508000000},{"sga":4627000000,"ebit":3751000000,"ebitda":5035000000,"period":"2025-03-31","revenue":13588000000,"epsBasic":1.88,"netIncome":2916000000,"rdExpense":3159000000,"epsDiluted":1.87,"grossProfit":11347000000,"operatingIncome":3674000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":0.97,"netIncome":null,"rdExpense":null,"epsDiluted":0.96,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":185.61,"previousClose":187.72,"fiftyTwoWeekHigh":212.71,"fiftyTwoWeekLow":134.14,"fiftyTwoWeekRange":"134.14 - 212.71","fiftyDayAverage":192.63,"twoHundredDayAverage":178.95,"beta":0.22,"enterpriseValue":317183295488,"forwardPE":31.4,"priceToBook":6.07,"priceToSales":4.76,"enterpriseToRevenue":5.25,"enterpriseToEbitda":15.86,"pegRatio":1.52,"ebitda":19993999360,"ebitdaMargin":33.1,"freeCashflow":6538874880,"operatingCashflow":14220999680,"totalDebt":34029000704,"debtToEquity":71.8,"currentRatio":0.91,"returnOnAssets":8.5,"returnOnEquity":23.5,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":224.49,"targetHighPrice":245,"targetLowPrice":184,"dividendRate":3.16,"payoutRatio":0.48,"fiveYearAvgDividendYield":2.12,"exDividendDate":1771545600,"insiderHeldPercent":0,"institutionHeldPercent":59.7,"sharesOutstanding":1550848083,"floatShares":1541471860,"sharesShort":1830898,"shortRatio":0.88,"shortPercentOfFloat":0.1,"epsTrailing":6.65,"epsForward":5.9,"revenuePerShare":39,"bookValue":30.56,"officers":[{"age":66,"name":"Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.","title":"CEO & Executive Director"},{"age":51,"name":"Dr. Aradhana  Sarin M.D.","title":"CFO & Executive Director"},{"age":55,"name":"Ms. Pam P. Cheng","title":"EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board"},{"age":null,"name":"Mr. Joris  Silon","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Jeffrey  Pott J.D.","title":"CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board"},{"age":null,"name":"Dr. Ruud  Dobber Ph.D.","title":"Executive Vice-President of BioPharmaceuticals Business Unit"},{"age":59,"name":"Dr. Susan Mary Galbraith M.D., Ph.D.","title":"Executive Vice President of Oncology R&D"},{"age":null,"name":"Ms. Iskra  Reic","title":"Executive Vice President of International"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.astrazeneca.com","phone":"44 20 3749 5000"}}